Article
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
European journal of cancer (Oxford, England : 1990) - 1 Oct 2018
Madi Ayman, Fisher David, Maughan Timothy S, Colley James P, Meade Angela M, Maynard Julie, Humphreys Vikki, Wasan Harpreet, Adams Richard A, Idziaszczyk Shelley, Harris Rebecca, Kaplan Richard S, Cheadle Jeremy P
Abstract excerpt
BACKGROUND: Inherited genetic variants may influence response to, and side-effects from, chemotherapy. We sought to generate a comprehensive inherited pharmacogenetic profile for oxaliplatin and 5FU/capecitabine therapy in advanced colorectal cancer (aCRC). METHODS: We analysed more than 200 potentially functional, common, inherited variants in genes within the 5FU, capecitabine, oxaliplatin and DNA repair...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.